Amendments to the Claims:

1. (Previously presented) A composition comprising:

(a) a pharmaceutically effective amount of reboxetine or a pharmaceutically effective salt thereof; and

(b) a pharmaceutically effective amount of one or more neuroleptic agents selected from clozapine, olanzapine and risperidone or a pharmaceutically effective salt thereof.

2. (Cancelled)

3. (Previously presented) The composition according to claim 1 wherein component (a) is reboxetine in either its racemic or +(S,S) enantiomeric form.

4. (Original) The composition according to claim 3 containing between about 0.1 mg to about 10 mg reboxetine.

5-6 (Cancelled)

7. (Original) The composition according to claim 1 wherein component (a) and component (b) are maintained in the same delivery vehicle.

8. (Original) The composition according to claim 1 wherein component (a) and component (b) are maintained in different delivery vehicles.

9. (Previously presented) A method for treating schizophrenia in a mammal comprising administering to said mammal a pharmaceutically effective amount of a composition comprising:

(a) a pharmaceutically effective amount of reboxetine or a pharmaceutically effective salt thereof; and

(b) a pharmaceutically effective amount of one or more neuroleptic agents selected from clozapine, olanzapine and risperidone or a pharmaceutically effective salt thereof.

10. (Cancelled)

11. (Original) The method of claim 9 wherein said composition is administered rectally, topically, orally, sublingually, intranasally, transdermally or parenterally.

12. (Original) The method according to claim 9 wherein component (a) and component (b) of said composition are simultaneously administered.

13. (Original) The method according to claim 9 wherein component (a) and component (b) of said composition are concomitantly administered.

14. (Cancelled)

15. (Original) The method according to claim 9 wherein component (a) of said composition comprises reboxetine in its racemic or enantiomeric form.

16. (Original) The method according to claim 15 wherein between about 0.1 mg to about 10 mg reboxetine is administered to the patient on a daily basis.

17. (Cancelled)

18. (Original) A composition consisting essentially of:

(a) a pharmaceutically effective amount of reboxetine in its racemic or enantiomeric form; and

(b) a pharmaceutically effective amount of one or more neuroleptic agents selected from the group consisting of clozapine, olanzapine, risperidone and mixtures thereof or a pharmaceutically effective salt thereof;

wherein components (a) and (b) are maintained in the same or in different delivery vehicles.

19-22 (Cancelled)

23. (New) A composition comprising:

(a) a pharmaceutically effective amount of reboxetine or a pharmaceutically effective salt thereof; and

(b) a pharmaceutically effective amount of clozapine or a pharmaceutically effective salt thereof.

24. (New) A composition comprising:

(a) a pharmaceutically effective amount of reboxetine or a pharmaceutically effective salt thereof; and

(b) a pharmaceutically effective amount of olanzapine or a pharmaceutically effective salt thereof.

25. (New) A composition comprising:

(a) a pharmaceutically effective amount of reboxetine or a pharmaceutically effective salt thereof; and

(b) a pharmaceutically effective amount of risperidone or a pharmaceutically effective salt thereof.